Gemcitabine trials for Breast cancer

All Gemcitabine trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Gemcitabine for Breast cancer

• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
  NCT06103864 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 320 locations
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 166 locations
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 295 locations
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  NCT06841354 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 280 locations
• ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
  NCT07007559 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
  NCT06026657 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
  NCT06492759 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
  NCT05601440 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 10 locations
• Organoid-based Functional Precision Therapy for Advanced Breast Cancer
  NCT06102824 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
  NCT06268652 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
  NCT07173751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 161 locations
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
  NCT05981001 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
  NCT06081959 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
  NCT07461454 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location

Common questions

How many trials study Gemcitabine for Breast cancer?

14 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.